Al-Ani Bahjat, Hollenberg Morley D
Diabetes/Endocrine and Mucosal Inflammation Research Groups, Department of Pharmacology, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada.
J Pharmacol Exp Ther. 2003 Mar;304(3):1120-8. doi: 10.1124/jpet.102.043844.
In intact cells, trypsin activates proteinase-activated receptor-2 (PAR(2)) by hydrolysis at residues R(36)/S(37) (amino acids are abbreviated by their one-letter code), revealing an active tethered ligand sequence. We sought to determine whether in intact cells, the tryptic cleavage/activation of PAR(2) might also be accompanied by hydrolysis at other potential N-terminal cleavage sites, like residues K(34), R(41), K(51), and K(72), as implied by the tryptic cleavage in vitro at these residues of Escherichia coli-expressed human N-terminal PAR(2)R(31)-P(79). To this end, four PAR(2) mutants with altered tryptic cleavage sites were prepared (PAR(2)R(36)A, PAR(2)S(37)P, PAR(2)R(41)A, and PAR(2)R(36)AR(41)A), expressed in Kirsten virus-transformed rat kidney cells and were evaluated together with the wild-type PAR(2)-expressing cells for 1) activation (Ca(2+) signaling) by trypsin and the receptor-activating peptide SLIGRL-NH(2) (SL-NH(2)) and 2) the tryptic release of two antigenic receptor determinants, one N-terminal to the R(36)/S(37) cleavage/activation site detected by SLAW-A antibody and the second (detected by antibody, B5), N-terminal to residues K(51), K(72). None of the mutants resistant to cleavage at R(36) were activated by trypsin, yet all retained reactivity to B5 and all were activated by SL-NH(2). In contrast, trypsin activated both wild-type and PAR(2)R(41)A, leading to a disappearance of SLAW-A but not B5 reactivity. We conclude that, as opposed to the E. coli-expressed PAR(2) N-terminal polypeptide, PAR(2) expressed in intact cells displays selective tryptic cleavage at the R(36)/S(37) activation site, without cleaving downstream. Thus, in intact cells, trypsin activation does not concurrently "disarm" rat PAR(2), but leaves the "tethered ligand" persistently attached to the body of the receptor.
在完整细胞中,胰蛋白酶通过水解R(36)/S(37)位点(氨基酸用单字母代码缩写)激活蛋白酶激活受体-2(PAR(2)),暴露出一个活性的拴系配体序列。我们试图确定在完整细胞中,PAR(2)的胰蛋白酶切割/激活是否也可能伴随着在其他潜在的N端切割位点的水解,如K(34)、R(41)、K(51)和K(72)位点,正如在体外对大肠杆菌表达的人N端PAR(2)R(31)-P(79)的这些位点进行胰蛋白酶切割所暗示的那样。为此,制备了四个胰蛋白酶切割位点改变的PAR(2)突变体(PAR(2)R(36)A、PAR(2)S(37)P、PAR(2)R(41)A和PAR(2)R(36)AR(41)A),在柯斯顿病毒转化的大鼠肾细胞中表达,并与表达野生型PAR(2)的细胞一起进行评估,以检测:1)胰蛋白酶和受体激活肽SLIGRL-NH(2)(SL-NH(2))对其的激活作用(Ca(2+)信号传导);2)两个抗原性受体决定簇的胰蛋白酶释放情况,一个在R(36)/S(37)切割/激活位点的N端,可被SLAW-A抗体检测到,另一个(被抗体B5检测)在K(51)、K(72)位点的N端。所有对R(36)切割有抗性的突变体都不能被胰蛋白酶激活,但都保留了对B5的反应性,并且都能被SL-NH(2)激活。相反,胰蛋白酶激活了野生型和PAR(2)R(41)A,导致SLAW-A反应性消失,但B5反应性未消失。我们得出结论,与大肠杆菌表达的PAR(2)N端多肽不同,完整细胞中表达的PAR(2)在R(36)/S(37)激活位点表现出选择性的胰蛋白酶切割,而不会在下游切割。因此,在完整细胞中,胰蛋白酶激活不会同时“解除”大鼠PAR(2) 的活性,而是使“拴系配体”持续附着在受体主体上。